Nature:癌细胞穿过血管壁发生转移机制被揭示

2016-08-12 佚名 生物谷

很多癌症仅当在体内其他地方形成转移瘤时才变成致命的危险。当单个癌细胞从原发性肿瘤中脱落下来,通过血液运行到达体内较远的部位时,继发性肿瘤(即转移瘤)就会形成。为了做到这一点,它们不得不穿过小血管壁。 如今,在一项新的研究中,来自德国马克斯普朗克心脏与肺部研究所、法兰克福大学的研究人员证实肿瘤细胞杀死血管壁中的特定细胞。这能够让它们离开血管和建立转移瘤,而且这种过程是由一种被称作死亡受体6(DR6

很多癌症仅当在体内其他地方形成转移瘤时才变成致命的危险。当单个癌细胞从原发性肿瘤中脱落下来,通过血液运行到达体内较远的部位时,继发性肿瘤(即转移瘤)就会形成。为了做到这一点,它们不得不穿过小血管壁。

如今,在一项新的研究中,来自德国马克斯普朗克心脏与肺部研究所、法兰克福大学的研究人员证实肿瘤细胞杀死血管壁中的特定细胞。这能够让它们离开血管和建立转移瘤,而且这种过程是由一种被称作死亡受体6(DR6)的分子所促进的。相关研究结果发表在2016年8月11日那期Nature期刊上,论文标题为“Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis”。

通过与来自德国科隆大学和海德堡大学的研究人员合作,马克斯普朗克心脏与肺部研究所药物学系主任Stefan Offermanns领导的一个研究团队成功地阐明了其背后的机制。研究人员首次利用体外培养的癌细胞开展实验,首先观察到单个肿瘤细胞如何杀死血管壁中的特定细胞,即血管内皮细胞。在实验室中,这种被称作坏死性凋亡(necroptosis)的过程能够让癌细胞穿过血管内皮细胞层。论文第一作者Boris Strilic说,“我们然后在小鼠体内开展的研究中证实同样的过程也在活的有机体中发生。”

研究人员也发现血管内皮细胞自身也释放出宣告它们自己死亡的信号:这些血管壁细胞(即血管内皮细胞)在它们的表面上含有受体分子DR6。Strilic解释道,“当癌细胞与DR6接触时,癌细胞表面上的蛋白APP激活它。这标志着癌细胞开始攻击血管壁,最终导致血管壁细胞发生坏死性凋亡。”

细胞膜上的死亡受体

Offermanns团队随后证实在经过修饰的让DR6不再发挥功能的小鼠体内,更少的血管内皮细胞发生坏死性凋亡,因而也就导致更少的肿瘤细胞转移。Strilic说,“在阻断DR6或癌细胞蛋白APP后,也会发现这种效果,因而证实了我们之前的观察结果。”

然而,仍然并不完全清楚的是癌细胞是否直接通过血管壁中形成的空隙迁移出去,或者存在一种间接作用:“我们有证据证实当血管壁细胞死亡时,有更多的分子释放出来,这些分子使得癌细胞更容易从周围的区域渗透出去”,Offermanns说道。

Offermanns说,“这种机制可能是治疗或阻止所形成的转移瘤的一个大有希望的起点。”然而,首先还必需确定阻断DR6是否产生不想要的副作用。而且还必需确定这些观察结果在多大程度上适用于人体。

原始出处:

Strilic B, Yang L, Albarrán-Juárez J, Wachsmuth L, Han K, Müller UC, Pasparakis M, Offermanns S. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016 Aug 3;536(7615):215-218.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2017-07-24 仁心济世
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2017-05-25 ycmayy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-09-03 1771ae4158m

    学习了,好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-21 lecoo

    如果是这样那阻断抑制剂可能是比较好的设想

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 曹~~

    那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 doctorJiangchao

    继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 doctorJiangchao

    继续学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 doctorJiangchao

    继续关注

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 doctorJiangchao

    继续学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1881255, encodeId=2ec91881255c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jul 24 12:40:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018073, encodeId=f3b620180e3ef, content=<a href='/topic/show?id=515b896022b' target=_blank style='color:#2F92EE;'>#血管壁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89602, encryptionId=515b896022b, topicName=血管壁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Thu May 25 09:40:00 CST 2017, time=2017-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110133, encodeId=967b11013397, content=学习了,好, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/23/ac01daf0962458a9eb8c0b1e2f6ce5bc.jpg, createdBy=04b81710322, createdName=1771ae4158m, createdTime=Sat Sep 03 08:13:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=102049, encodeId=518110204923, content=如果是这样那阻断抑制剂可能是比较好的设想, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1ab1619415, createdName=lecoo, createdTime=Sun Aug 21 17:48:00 CST 2016, time=2016-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98708, encodeId=105298e082a, content=那我们可以通过拮抗或者先占据死亡受体从而达到延缓转移瘤的发生?可以这么想吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/480e473525086e460ea4d127e19516f7.jpg, createdBy=48ac1935401, createdName=曹~~, createdTime=Sun Aug 14 22:32:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98695, encodeId=19c19869559, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98694, encodeId=bf28986945c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 21:52:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98503, encodeId=094f9850322, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98504, encodeId=7fa2985048c, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Aug 14 16:00:00 CST 2016, time=2016-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98397, encodeId=00859839e6b, content=学习了,期待进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Sun Aug 14 14:25:00 CST 2016, time=2016-08-14, status=1, ipAttribution=)]
    2016-08-14 明崖

    学习了,期待进一步发展

    0

相关资讯

血管竟然可以这样疏通!!!

导语:点播放后,根本停不下来。 点击图片,即可跳转进入视频观看界面,请处于WiFi条件下观看,土豪随意。

血管稳态与重构的调控机制重大研究计划项目指南

血管稳态与重构的调控机制重大研究计划2016年度项目指南 本重大研究计划旨在通过对血管稳态与重构的机制中涉及的代谢、氧化应激、炎症、生物活性物质、遗传和表观遗传调控等问题的研究,深入探讨血管稳态维持及血管重构的分子机制,揭示血管重构的本质,产生新的用于重大血管疾病的早期诊断、干预策略和防治模式。 本重大研究计划从2013年开始,已资助17个重点支持项目和78个培育项目。根据立项

癌症细胞补给线或为药物研发提供新靶标

图片来源:V. ALTOUNIAN/SCIENCE 如果血管生成拟态的确为转移铺就了道路,那么阻止它就会拯救生命。 2000年3月的一个大冷天,上百位研究人员挤在美国盐湖城一个宾馆的礼堂内,迫切想观看就癌症研究中最具争议性的观点发起的终极对决。一边是爱荷华大学癌症中心癌症生物学家Mary Hendrix。1年前,她的团队报告称,肿瘤细胞能利用血液供应获取营养物质。这是一

5·18血管健康日--血脂10问

作者:河北省人民医院 郭艺芳每年5月18日是“血管健康日”。冠心病与脑中风是对我国居民生命健康危害最大的疾病,这些基本本质上都属于血管疾病。积极筛查并干预血脂异常对于维护血管健康具有重要意义。1、什么是血脂?——血脂是血液中胆固醇、甘油三酯(TG)和类脂的总称。在多数医院所提供的化验单中,血脂检验项目主要包括胆固醇和TG两组参数。总胆固醇(TC)又被分为高密度脂蛋白胆固醇(HDL-C)和低密度

JAHA:创伤后应激障碍患者的血管健康备受影响

一项新研究表明,创伤后应激障碍(PTSD)可能会降低退伍军人血管扩张的能力,增加他们心脏病发作和卒中的风险。研究发表在Journal of the American Heart Association。 这是迄今为止最大规模探究创伤后应激障碍(PTSD)对退伍军人血管健康影响的研究。研究人员发现,相比正常人而言,创伤后应激障碍的退伍军人扩张通血管的能力降低,血管活性降低,出现心脏病和其他严重并发症